Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 29, 2002
Business Overview: Illumina develops next-generation tools for large-scale genetic analysis, including custom oligonucleotides, SNP genotyping services, and proprietary BeadArray technology. The company is in an early-stage commercialization phase, transitioning from research grants to product and service sales.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 29, 2002 |
Nine Months Ended Sep 29, 2002 |
Nine Months Ended Sep 30, 2001 |
|---|---|---|---|
| Total Revenue | $2,985 | $6,154 | $1,725 |
| Net Loss | $(7,602) | $(32,715) | $(16,596) |
| Net Loss Per Share (Basic/Diluted) | $(0.24) | $(1.06) | $(0.56) |
| Cash and Cash Equivalents | $1,185 | $73,724 (Total Cash, Equivalents, and Investments) | |
| Investments (Available for Sale) | $72,539 | ||
| Total Debt (Current + Long-term) | $26,114 | $25,784 (Dec 30, 2001: $0) | |
| Accrued Litigation Judgment | $7,860 | ||
| Stockholders' Equity | $78,695 | $106,791 (Dec 30, 2001) | |
| Accumulated Deficit | $(82,800) |
Note: Revenue breakdown for the nine months ended Sep 29, 2002: Product ($2.9M), Service ($1.2M), Research ($2.1M).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the nine months ended September 29, 2002, increased to $6.2 million from $1.7 million in the prior year period. This was driven by a 300% increase in product sales (oligonucleotides) and the initiation of service revenues ($1.2M) which were non-existent in the prior year.
- Operating Expenses: Operating expenses rose significantly to $40.0 million for the nine-month period (vs. $23.1 million in 2001). Research and Development (R&D) expenses increased by $5.9 million to $20.5 million due to headcount growth and BeadArray development. Selling, General, and Administrative (SG&A) expenses increased by $2.6 million to $6.3 million.
- One-Time Litigation Charge: A material non-recurring charge of $7.7 million was recorded in the second quarter of 2002 related to a termination-of-employment lawsuit. This charge significantly impacted the net loss for the period.
- Debt and Liquidity: The company assumed a $26.0 million mortgage in January 2002 for the purchase of a new facility, resulting in a substantial increase in long-term debt compared to the prior year. Cash used in operating activities increased to $19.7 million (vs. $7.9 million in 2001), while cash provided by financing activities was $26.3 million, primarily from the new mortgage proceeds.
Guidance, Outlook, and Risks
- Product Launch: Illumina announced plans to launch its own high-throughput SNP genotyping system in the fourth quarter of 2002, following delays in a collaboration with Applied Biosystems. The company expects to retain all operating profits from this system rather than sharing them.
- Profitability Outlook: Management expects to continue incurring substantial and increasing operating losses as it scales R&D and builds sales infrastructure. Significant revenue growth is required to achieve profitability.
- Litigation Contingency: The company is appealing the $7.7 million employment judgment. To secure the appeal, Illumina filed a surety bond of approximately $11.3 million, requiring the restriction of approximately $12.5 million in marketable securities as collateral for 12-18 months.
- Liquidity: Management believes current cash, investments, and funding from alliances/grants are sufficient to fund operations for at least the next 24 months. However, additional funding may be required depending on the success of commercialization and the litigation appeal.
- Risks: Key risks include the failure to commercialize new products, delays in the Applied Biosystems collaboration, intense competition, reliance on a limited number of suppliers for key components, and the potential need for dilutive equity financing.
Investor Verification Checklist
- Litigation Impact: Verify the status of the appeal regarding the $7.7 million judgment and the potential for additional interest accruals or legal fees.
- Restricted Assets: Confirm the impact of the $12.5 million in restricted marketable securities on the company's available liquidity for operations.
- Product Commercialization: Monitor the Q4 2002 launch timeline for the proprietary SNP genotyping system and initial order intake.
- Collaboration Status: Assess the likelihood of the Applied Biosystems collaboration product launch, given the reported lack of progress and potential for arbitration.
- Burn Rate: Track the rate of cash consumption given the increased R&D and SG&A expenses and the new debt service obligations ($2.5M annual payments).